4342 - 97 street NW
Edmonton, AB T6E 5R9
Canada
780-448-1400
https://www.questpharmatech.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Ragupathy Madiyalakan Ph.D. | CEO & Director | 215k | N/A | N/A |
Mr. Pierre Vermette C.A., CPA | Chief Financial Officer | 74.17k | N/A | N/A |
Mr. Roger Andrews | Head of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Mr. Douglas C. Bachman | Vice President of Corporate Development | 37.94k | N/A | 1954 |
Mr. Thomas Woo | Vice President of Product Development | N/A | N/A | N/A |
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Quest PharmaTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.